Ms Julie Locklear | Vice President and Head of Health Economics and Outcomes Research
E.M.D. Serono Inc

Ms Julie Locklear, Vice President and Head of Health Economics and Outcomes Research, E.M.D. Serono Inc

Julie Locklear, PharmD, MBA is Vice President and Head for Health Economics & Outcomes Research (HEOR) at EMD Serono, Inc, a business of Merck KGaA, Darmstadt, Germany. Dr. Locklear joined EMD Serono, Inc. in January 2013. In this role, she is responsible for establishing the US Health Economics & Outcomes Research team within the Medical Affairs Organization. Leadership of a team responsible for developing, executing and disseminating the value evidence of EMD Serono's portfolio of specialty products in the areas of oncology, immuno-oncology, immunology, neuroscience, infertility, and endocrinology. Ensures US payer customer needs are aligned with cross-functional partners across the US and Global organizations. Leads a team of in-house HEOR researchers who generate value evidence as well as field-based HEOR team who interact with formulary decision makers.

Her previous experience includes seven years as Global Payer Evidence Director at AstraZeneca Pharmaceuticals where her responsibilities focused on the development of successful global reimbursement dossiers across multiple therapeutic areas including inflammation, respiratory, neuroscience and autoimmune disorders. She has experience launching products, business development, market access, leading cross functional internal teams (direct and indirect management), external contract research organizations, and alliance management.

Prior to AstraZeneca, she worked for Janssen Pharmaceutica in a variety of health economic roles including both in-house and customer facing. Dr. Locklear received her Doctor of Pharmacy from the University of Rhode Island and a Masters in Business Administration from Saint Joseph’s University. She currently sits on the board of Network for Excellence in Health Innovation (NEHI) and sits on a number of executive-level real-world evidence (RWE) roundtable discussions.

back to speakers